Skip to main content

Advertisement

Table 5 Post-treatment changes in lymphocytes

From: Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

  Post-treatment percentage change from baseline (mean ± SD)
Parameter 6 weeks 10 weeks 18 weeks 32 weeks
Lymphocytes n = 14 n = 12 n = 11 n = 7
B cells -54%a ± 25% -45%a ± 47% -39%a ± 23% -31%a ± 33%
T cells 2% ± 36% -6% ± 34% 1% ± 13% -5% ± 19%
  1. aDenotes statistical significance of the observed median change-from-baseline value with P ≤ 0.05 by Wilcoxon signed rank test. None of the changes from baseline in T cells was statistically significant. SD, standard deviation.